<DOC>
	<DOCNO>NCT00401128</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine irinotecan , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase II trial study side effect well give gemcitabine together irinotecan work treat patient metastatic kidney cancer .</brief_summary>
	<brief_title>Gemcitabine Irinotecan Treating Patients With Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient epithelial ( clear nonclear cell ) renal cell carcinoma ( RCC ) treat gemcitabine hydrochloride irinotecan hydrochloride . - Compare response patient clear cell RCC v nonclear cell RCC treat regimen . - Determine toxicity regimen . OUTLINE : This open-label study . Patients receive gemcitabine hydrochloride IV 30 minute irinotecan hydrochloride IV 90 minute day 1 8 . Treatment repeat every 21 day least 6 course absence unacceptable toxicity disease progression . After completion study treatment , patient follow every 3 month 1 year . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm epithelial renal cell carcinoma ( RCC ) , include either clear cell nonclear cell RCC Strong clinical evidence biopsy proof metastases site site distant primary tumor Measurable disease No untreated progressive CNS metastases PATIENT CHARACTERISTICS : ECOG performance status 01 Life expectancy &gt; 3 month Absolute neutrophil count &gt; 1,500/mm³ Platelet count &gt; 100,000/mm³ Hemoglobin &gt; 9.5 g/dL Creatinine ≤ 1.8 mg/dL Bilirubin &lt; 1.5 mg/dL Calcium &lt; 11.5 mg/dL ALT AST &lt; 3 time upper limit normal No history follow : Serious cardiac arrhythmia cardiac arrhythmia require treatment Congestive heart failure Angina pectoris Other severe cardiovascular disease produce limitation physical activity ( i.e. , New York Heart Association class IIIIV heart disease ) No prior malignancy except follow : Basal cell squamous cell carcinoma skin Carcinoma situ uterine cervix Any malignancy treat curative intent complete remission &gt; 3 year No active peptic ulcer disease , inflammatory bowel disease , chronic diarrhea No local systemic infection require IV antibiotic within past 28 day Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Recovered prior hormonal therapy , radiotherapy , biologic therapy , chemotherapy No 3 prior therapeutic regimen metastatic disease No prior organ allograft More 28 day since prior major surgery require general anesthesia More 28 day since prior radiotherapy control pain skeletal lesion More 28 day since prior hormonal treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>clear cell renal cell carcinoma</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>papillary renal cell carcinoma</keyword>
	<keyword>stage IV renal cell cancer</keyword>
</DOC>